Saruparib
CAS No. : 2589531-76-8
(Synonyms: AZD5305)
| Size | Price | Stock |
|---|---|---|
| 1mg | $142 | In-stock |
| 5mg | $300 | In-stock |
| 10mg | $480 | In-stock |
| 25mg | $950 | In-stock |
| 50mg | $1450 | In-stock |
| 100mg | $2250 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-132167 |
| M.Wt: | 406.48 |
| Formula: | C22H26N6O2 |
| Purity: | >98 % |
| Solubility: | DMSO : 12.5 mg/mL (ultrasonic;warming;heat to 60°C) |
Saruparib (AZD5305) is a potent, orally active and selective PARP inhibitor and trapper with IC50 values of 3 nM and 1400 nM for PARP1 and PARP2, respectively. Saruparib has anti-proliferative activity and inhibits growth in cells with deficiencies in DNA repair[1][2].
In Vitro:Saruparib (AZD5305) (0.1 nM-100 μM) inhibits PARylation in A549 WT cells by selectively blocking PARP1 enzymatic activity with an IC50 value of 2.3 nM[1].
AZD5305 (0.1 nM-100 μM; A549 WT cells) is a potent and selective trapper of PARP1 in a dose-dependent manner by single digit nanomolar concentrations[1].
AZD5305 (0.1 nM-100 μM; 48 h; DLD1 WT and DLD1 BRCA2-/-) has anti-proliferative activity and targets cancer cells with HRR-deficiency, inducing DNA damage accumulation and cell-cycle arrest[1].
In Vivo:Saruparib (AZD5305) (0.01-0.3 mg/kg; p.o.; daily, for 35 d; female Han Wistar rats) demonstrates sustained antitumor activity in BRCAm xenograft and PDX models in vivo[1].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- Saruparib
- Cat. No.:
- HY-132167
- Quantity:
Your information is safe with us.